Retatrutide in plain English — the triple agonist that may eclipse tirzepatide
8 min read · Uplevel editorial
You've been on tirzepatide for six months. The first three were dramatic — ten pounds the first month, then eight, then seven. The nausea became manageable. The appetite that had organized your life for decades became something you could ignore for hours at a time. And then, somewhere around month four or five, the number on the scale stopped moving. Not reversed. Not stalled terribly. Just plateaued at a point that isn't where you were hoping to be. Your prescribing provider says this is expected. The dose is at its maximum. Your body has found a new equilibrium.
This experience is common enough that it has a name in the obesity medicine literature — the weight loss plateau — and it's not a failure of the drug or the patient. It's biology. The body has multiple systems for defending its weight, and a drug that works through one or two pathways eventually encounters the ones it doesn't touch. Retatrutide is, in part, an attempt to address that problem. It is a triple agonist — a single peptide molecule that simultaneously activates three receptors — and the third receptor is the one that targets a mechanism the current class of drugs mostly doesn't reach.
To understand what retatrutide does, it helps to understand the three receptors it activates and what each one contributes.
GLP-1 receptor agonism is the foundation. The GLP-1 receptor is present in the pancreatic beta cells, the gut, the vagus nerve, and the hypothalamus. Activating it stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying so food clears the stomach more slowly, and — critically for weight management — signals the hypothalamus to reduce appetite and food intake. GLP-1 receptor agonism is responsible for the appetite suppression that semaglutide and tirzepatide users describe: the quieting of food noise, the reduced urgency around eating, the ability to stop at a smaller portion without the preoccupied, searching quality of unsatisfied hunger. This mechanism is well-characterized and the cornerstone of the entire GLP-1 drug class.
GIP receptor agonism is tirzepatide's addition to the equation. GIP — glucose-dependent insulinotropic polypeptide — is the other major incretin hormone, released from K-cells in the duodenum and proximal small intestine in response to fat and carbohydrate intake. Its role in human metabolism is more complex and, for a long time, was less well understood than GLP-1's. GIP receptor activation potentiates insulin secretion alongside GLP-1, but its contribution to appetite appears to work through distinct central pathways. In the hypothalamus, GLP-1 and GIP receptors are expressed in partially overlapping but distinct neuronal populations, and dual agonism appears to produce appetite suppression greater than either receptor alone — not just additive, but potentially synergistic in some circuits. GIP receptor activation may also influence adipose tissue metabolism directly. Whatever the precise mechanism, the SURMOUNT trials established that tirzepatide's dual agonism produces approximately 20-22% mean weight loss over 72 weeks — meaningfully more than semaglutide's roughly 15% over a similar period.
The glucagon receptor is retatrutide's new piece. And it requires some explanation, because glucagon has historically been framed as the enemy in metabolic disease.
Glucagon is GLP-1's ancient sibling, cleaved from the same proglucagon precursor in the pancreatic alpha cells. It raises blood sugar. When glucose is low, alpha cells release glucagon, the liver responds by producing glucose, and blood sugar comes back up. In type 2 diabetes and obesity, glucagon secretion is chronically elevated and poorly regulated — glucagon is supposed to be suppressed after meals, but in insulin-resistant states it isn't, which contributes to elevated fasting and post-meal glucose. This is part of why GLP-1 receptor agonists suppress glucagon and why that suppression helps blood sugar management. Making a drug that also activated the glucagon receptor seemed, from this vantage point, counterproductive.
The reconsideration came from looking at where else the glucagon receptor is expressed and what it does there. In brown adipose tissue and in skeletal muscle, glucagon receptor activation increases thermogenesis — the production of heat from metabolic processes that would otherwise go into stored energy. Brown fat, when it's activated by cold or certain hormonal signals, burns substantial amounts of calories through a process called non-shivering thermogenesis. Glucagon is one of the signals that activates it. In the liver, glucagon receptor activation promotes fat oxidation — the liver shifts toward burning fatty acids rather than storing them, which is relevant both for energy expenditure and for the fatty liver that accompanies metabolic syndrome and obesity. At the right dose, balanced against GLP-1 receptor activation that keeps glucose from rising inappropriately, the glucagon component adds a thermogenic effect that neither GLP-1 nor GIP receptor agonism provides on their own.
This is the logic of the triple agonist: GLP-1 handles appetite and glucose regulation, GIP adds complementary appetite suppression and insulin sensitization, and glucagon turns up the calorie-burning dial. Three levers pulling in coordinated directions.
Retatrutide is a 39-amino-acid peptide developed by Eli Lilly, designed with a fatty acid modification that extends its half-life to approximately a week — allowing once-weekly injection, consistent with the tirzepatide dosing schedule that patients and prescribers have accepted. The glucagon receptor activation in retatrutide is dose-dependent, and the relative balance of receptor activation shifts across the dose range: at lower doses the GLP-1 component dominates, and at higher doses the glucagon component becomes more prominent. This is pharmacologically important because it means the side-effect and efficacy profile changes across the dose range in a way that requires careful titration.
The Phase II trial results, published in the New England Journal of Medicine in 2023 (Jastreboff et al.), showed mean body weight reductions of approximately 24% at the highest dose tested — 12 mg weekly — over 48 weeks. The lower doses showed proportionally lower weight loss: roughly 8-9% at 1 mg, approximately 17% at 4 mg, and approximately 22-23% at 8 mg. The dose-response relationship was clear and steep. For context: tirzepatide's Phase III SURMOUNT-1 trial showed approximately 20-22% mean weight loss over 72 weeks at the highest approved doses. Retatrutide's Phase II data — at a shorter timepoint and in a smaller trial — exceeded that. Phase II and Phase III trials aren't directly comparable, and the number of participants, dropout rates, baseline characteristics, and statistical handling all differ in ways that make direct comparisons unreliable. But the direction is notable.
What about the glucagon component's effect on blood sugar? In the Phase II trial, the higher-dose retatrutide groups showed increased fasting glucose relative to the lower-dose groups — a predictable consequence of more glucagon receptor activation. This was not clinically severe in the trial population, which consisted of adults with obesity or overweight without type 2 diabetes, but it is a genuine pharmacological signal that will need to be managed carefully in people with metabolic disease. The GLP-1 component provides counterbalancing insulin stimulation, but the equilibrium between these effects depends on the individual's beta cell function and insulin sensitivity. This is one reason the Phase III program — the TRIUMPH trials — is studying retatrutide in both people with and without type 2 diabetes with attention to glycemic parameters.
The side-effect profile at the highest doses was similar in character to the rest of the GLP-1 class — nausea, vomiting, diarrhea, constipation, reduced appetite — but somewhat more pronounced. At 12 mg, a higher proportion of participants reported gastrointestinal adverse events than at lower doses, which is consistent with the steeper weight loss and the more aggressive receptor activation at that dose. The titration schedule used in the trial started low and escalated over months, which is the standard approach for managing GI tolerability in this class.
Whether retatrutide will be approved, and at what doses, depends on what the TRIUMPH Phase III trials show. Phase III data is still emerging. The drug is not approved anywhere as of mid-2025. The enthusiasm in the metabolic medicine community is real, but Phase III trials in larger, more diverse populations with longer follow-up often produce results that differ from Phase II in ways that matter — whether in effect size, side-effect frequency, or the identification of populations that respond differently. Retatrutide's Phase III results will tell the story that Phase II can only suggest.
What the Phase II data offers — honestly, without overstating it — is evidence that the triple receptor mechanism produces weight loss that the dual mechanism doesn't fully capture. That the glucagon component appears to add something measurable. That the dose-response relationship is steep enough to require careful clinical management. And that the next chapter of incretin pharmacology is not going to be about finding a better GLP-1 agonist — it's going to be about finding the best combination of receptors, at the best ratios, for the most people.
For people currently on tirzepatide who have plateaued, retatrutide represents a different biological approach rather than a more-of-the-same approach. Whether it becomes available and at what timeline is genuinely uncertain. But the mechanism tells a coherent story — and the Phase II data suggests the story might be as good as the theory.
Frequently asked